Awarded Grants

Awarded Grants

MDBR, CF Million Dollar Bike Ride MDBR, CF Million Dollar Bike Ride

Pharmacological strategies to target nonsense mutations in cystic fibrosis

Luis Juan Vicente Galietta

Fondazione Telethon - TIGEM

$54,718

Awardee: Luis Juan Vicente Galietta

Institution: Fondazione Telethon - TIGEM

Award Amount: $54,718

Final Report Lay Summary:

Cystic fibrosis (CF), one of most frequent and severe genetic diseases, affects multiple organs but

the consequences to the lungs are the most important ones for morbidity and mortality. The basic

defect in CF is the loss of function of CFTR, a plasma membrane chloride channel expressed in

various epithelial cell types. There are multiple types of CF-causing mutations that impair the

expression, maturation, and/or gating of CFTR protein. Importantly, some types of CFTR mutants

can be treated with drugs named correctors and potentiators. However, nonsense mutations, also

known as premature termination codons (PTCs), which cause the production of a truncated CFTR,

remain without an effective treatment. The overall goal of our project was to develop strategies to

target PTCs. In our experiments, cells expressing mutant CFTR were treated with combinations of

compounds acting at different levels on CFTR biosynthesis and function. We have identified the

most effective treatments for each mutation. In particular, we found that W1282X is the most

sensitive mutation with a large recovery mutant CFTR function, close to 30% of normal CFTR.

Y122X, G542X, and R1162X mutations could be also treated (10% of normal function) using

12 different combinations of compounds. In contrast, R553X mutation was particularly refractory to

pharmacological treatment. The results in our study will pave the way for future clinical trials in

which patients with specific mutations will be treated with the most appropriate compound

combinations.

Read More